Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study

被引：12
作者：
Eren, Orhan Onder [1 ]
Ozturk, Mehmet Akif [2 ]
Sonmez, Ozlem Uysal [1 ]
Oyan, Basak [1 ]
机构：
[1] Yeditepe Univ Hosp, Dept Clin Oncol, Istanbul, Turkey
[2] Yeditepe Univ Hosp, Dept Internal Med, Istanbul, Turkey
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2016年 / 23卷 / 06期
关键词：
gastric; cancer; maintenance; capecitabine; PHASE-III; 1ST-LINE CHEMOTHERAPY; PLUS CAPECITABINE; CISPLATIN; THERAPY; OXALIPLATIN; FLUOROURACIL; METAANALYSIS; MULTICENTER; IRINOTECAN;
D O I：
10.1097/MJT.0000000000000156
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Gastric cancer is still one of the cancers with highest mortality. Most patients present with advanced-stage disease. Palliative chemotherapy is usually the only treatment option for patients with advanced gastric cancer (AGC). Maintenance chemotherapy is an evolving concept in medical oncology. Maintenance chemotherapy can be administered with the same drug(s) in the initial regimen or with an alternative agent. In this article, we report our experience with capecitabine as a maintenance agent for patients with AGC. No treatment-related death was observed due to use of capecitabine. Median progression-free survival was 10.4 months, and median overall survival was 19.7 months. Activity and toxicity profile of capecitabine seems favorable as a maintenance agent in AGC. We believe that capecitabine deserves further trials as a maintenance agent for patients with AGC.
引用
收藏
页码：E1493 / E1497
页数：5
相关论文
共 25 条
[11]   First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status [J].
Hwang, Jun-Eul ;
Kim, Ha-Na ;
Kim, Dae-Eun ;
Shim, Hyun-Jeong ;
Bae, Woo-Kyun ;
Hwang, Eu-Chang ;
Cho, Sang-Hee ;
Chung, Ik-Joo .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (04) :562-568
[12]   Cytotoxicity Comparison of the Nanoparticles Deposited on Latex Rubber Bands between the Original and Stretched State [J].
Lee, Jung-Hwan ;
Lee, Eun-Jung ;
Kwon, Jae-Sung ;
Hwang, Chung-Ju ;
Kim, Kyoung-Nam .
JOURNAL OF NANOMATERIALS, 2014, 2014
[13]  
Moriguchi S, 1992, Surg Oncol, V1, P341, DOI 10.1016/0960-7404(92)90034-I
[14]   Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer [J].
Okines, A. F. C. ;
Norman, A. R. ;
McCloud, P. ;
Kang, Y. -K. ;
Cunningham, D. .
ANNALS OF ONCOLOGY, 2009, 20 (09) :1529-1534
[15]   PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Paz-Ares, Luis G. ;
de Marinis, Filippo ;
Dediu, Mircea ;
Thomas, Michael ;
Pujol, Jean-Louis ;
Bidoli, Paolo ;
Molinier, Olivier ;
Sahoo, Tarini Prasad ;
Laack, Eckart ;
Reck, Martin ;
Corral, Jesus ;
Melemed, Symantha ;
John, William ;
Chouaki, Nadia ;
Zimmermann, Annamaria H. ;
Visseren-Grul, Carla ;
Gridelli, Cesare .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2895-+
[16]   Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer [J].
Perol, Maurice ;
Chouaid, Christos ;
Perol, David ;
Barlesi, Fabrice ;
Gervais, Radj ;
Westeel, Virginie ;
Crequit, Jacky ;
Lena, Herve ;
Vergnenegre, Alain ;
Zalcman, Gerard ;
Monnet, Isabelle ;
Le Caer, Herve ;
Fournel, Pierre ;
Falchero, Lionel ;
Poudenx, Michel ;
Vaylet, Fabien ;
Segura-Ferlay, Celine ;
Devouassoux-Shisheboran, Mojgan ;
Taron, Miquel ;
Milleron, Bernard .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3516-3524
[17]   Capecitabine in the treatment of esophageal and gastric cancers [J].
Popa, Elizabeta C. ;
Shah, Manish A. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (12) :1645-1657
[18]   Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation [J].
Qiu, Miao-zhen ;
Wei, Xiao-li ;
Zhang, Dong-sheng ;
Jin, Ying ;
Zhou, Yi-xin ;
Wang, De-shen ;
Ren, Chao ;
Bai, Long ;
Luo, Hui-yan ;
Wang, Zhi-qiang ;
Wang, Feng-hua ;
Li, Yu-hong ;
Yang, Da-jun ;
Xu, Rui-hua .
TUMOR BIOLOGY, 2014, 35 (05) :4369-4375
[19]   A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma [J].
Roy, A. C. ;
Park, S. R. ;
Cunningham, D. ;
Kang, Y. K. ;
Chao, Y. ;
Chen, L. T. ;
Rees, C. ;
Lim, H. Y. ;
Tabernero, J. ;
Ramos, F. J. ;
Kujundzic, M. ;
Cardic, M. B. ;
Yeh, C. G. ;
de Gramont, A. .
ANNALS OF ONCOLOGY, 2013, 24 (06) :1567-1573
[20]  
Shah MA, 2010, J CLIN ONCOL S, V28, p15s
123